NASDAQ: FATEFate Therapeutics Inc Stock
$2.92-0.10 (-3.31%)
Updated Jul 2, 2026
FATE Price
$2.92
Fair Value Price
-$0.51
Market Cap
$340.35M
52 Week Low
$0.91
52 Week High
$3.21
P/E
-2.68x
P/B
1.89x
P/S
22.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.32M
Earnings
-$129.91M
Gross Margin
100%
Operating Margin
-2,056.79%
Profit Margin
-2,056.8%
Debt to Equity
0.59
Operating Cash Flow
-$103M
Beta
1.73
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FATE Overview
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FATE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FATE
Ranked#174 of 463
Ranked#174 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important FATE news, forecast changes, insider trades & much more!
FATE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FATE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FATE ($2.92) is overvalued by 673% relative to our estimate of its Fair Value price of -$0.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FATE ($2.92) is not significantly undervalued (673%) relative to our estimate of its Fair Value price of -$0.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FATE due diligence checks available for Premium users.
Valuation
FATE fair value
Fair Value of FATE stock based on Discounted Cash Flow (DCF)
Price
$2.92
Fair Value
-$0.51
Undervalued by
673.00%
FATE ($2.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FATE ($2.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FATE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.68x
Industry
17.59x
Market
8.54x
FATE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.89x
Industry
5.6x
FATE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FATE's financial health
Profit margin
Revenue
$1.3M
Net Income
-$31.2M
Profit Margin
-2,402.8%
FATE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FATE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$284.9M
Liabilities
$105.2M
Debt to equity
0.59
FATE's short-term assets ($179.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FATE's short-term assets ($179.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FATE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FATE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.8M
Investing
$23.6M
Financing
$0.0
FATE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FATE vs Biotech Stocks
Fate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.